Assessing the Potential for Improved Joint Health and Wellbeing by Providing a Whole Salmon Oil With Undenatured Type II Collagen Compared to Type II Collagen Alone

NCT ID
NCT07875101
Registry status
Not yet recruiting
Study type
Interventional
Phase
Not applicable
Sponsor
Hofseth Biocare ASA
Conditions
Joint Discomfort, Quality of Life, Wellbeing

Overview

ClinicalTrials.gov lists this study as Not yet recruiting.

Official title: A Decentralized, Active-Controlled Clinical Trial Investigating the Combination of NT-II® Salmon Bone Undenatured Type II Collagen and OmeGo® Salmon Oil Versus UC-II® Undenatured Chicken Type II Collagen on Knee Pain, Function, and Inflammatory Biomarkers in Adults Who Regularly Suffer From Mild to Moderate Knee Discomfort

Enrollment: 150 participants (Estimated).

What is being studied

  • Dietary supplement: Undenatured collagen
  • Dietary supplement: Whole salmon oil

Who may be eligible

Ages
40 Years to 75 Years
Sex
All
Healthy volunteers accepted
Yes

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * Males and females aged 40-75 years * Knee pain which decreases with rest present for at least 3 months prior to screening * Knee pain VAS ≥30 mm and 75 mm in more painful knee at screening (=index knee) * Generally fit and active * BMI 18.5-32.5 kg/m² * Good overall physical and mental health * Ability to provide written informed consent and comply with all study procedures * Access to a smartphone and willingness to use the Alethios digital platform Exclusion Criteria: * Known allergy or hypersensitivity to fish, salmon, or chicken-derived products * Pregnancy, breastfeeding, or planned pregnancy during the study period * Secondary OA (e.g., post-traumatic, inflammatory arthritis, rheumatoid arthritis) * Planned or prior knee surgery within 6 months of study entry * Intra-articular injections (corticosteroid or hyaluronic acid) within 3 months of Day 0 * Chronic back, hip or foot pain affecting ambulation * Systemic corticosteroid therapy within 4 weeks of Day 0 * Use of opioid-based treatments for pain relief * Continuous use of any analgesia including acetaminophen and NSAIDs * Active bleeding disorders or use of anticoagulant therapy (warfarin, novel oral anticoagulants) * Participation in another clinical trial within 30 days of Day 0 * Use of joint supplements - glucosamine, chondroitin, collagen supplements, boswellia, curcumin or omega-3 supplements within 4 weeks of Day 0 (washout required) * Regular use of proton pump inhibitors (e.g. omeprazole, esomeprazole etc) of ≥3 times per week within the past month * Unstable weight (±5 kg in past 3 months) or significant dietary changes * Any significant systemic disease that, in the investigator's judgment, would interfere with study participation or safety * Inability or unwillingness to comply with study procedures

Study locations

1 study location is listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: United States

  • California, United States: 1

Sample of listed locations

  • Alethios Inc. — San Francisco, California, 94109, United States — Site recruitment status not specified in the registry data

Study details

Start date
October 30, 2026
Primary completion date
January 30, 2027
Completion date
February 15, 2027
First posted
October 15, 2026
Collaborators
Alethios, Inc.

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07875101
Registry last updated
October 15, 2026
QualifiedStudies registry data refreshed
October 19, 2026
QualifiedStudies record fetched
October 19, 2026

View NCT07875101 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Knee Pain studies | Clinical trial FAQ